27.7 C
Vientiane
Monday, September 22, 2025
spot_img

Cision PR Newswire

Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide...

-          The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of vomiting was 6.7% in ASC47 in combination with semaglutide group compared to 57.1% in the semaglutide monotherapy group. -          Ultra-long-acting subcutaneous (SQ) depot formulation of ASC47...

Ecolab Recognizes Chandra Asri Group and Aster with Southeast Asia Impact Awards for Water Conservation Leadership

SINGAPORE, Sept. 22, 2025 /PRNewswire/ -- Ecolab Inc., a global leader in sustainability solutions for...

in-cosmetics Asia 2025: Global ingredients and innovations for Japanese beauty industry

Event offers Japanese beauty experts access to more than 700 suppliers, hands-on formulation lessons...

WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends

SHANGHAI, Sept. 22, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a...

22nd China-ASEAN Expo Yields 155 Project Agreements

BEIJING, Sept. 22, 2025 /PRNewswire/ -- A news report from CRI Online:  On September...